Why Pharma Can’t Treat AI Tools Like Google

A researcher looking up a formula on Google gets back a page someone else already published. Nothing about that search leaves the browser except, at most, an ad profile. Increasingly, people across pharma and life sciences use AI writing and research tools the same way. Type in a question, paste in a paragraph, get an answer back, move on. It feels like search. It behaves like something else entirely.

Every prompt sent to a public AI tool is processed, and in many cases stored, on servers outside the organization that typed it. For pharma, where a single paragraph might contain unpublished trial data, a novel synthesis route, or patient-adjacent clinical detail, that difference is a real exposure, not a hypothetical one.

The Habit Behind the Risk

Most professionals didn’t decide to take on this risk. They inherited a workflow. A regulatory affairs associate under deadline pastes submission language into an AI tool to tighten the phrasing. A bench scientist summarizes lab notes to save time on a weekly update. None of this feels like a security decision. It feels like using a better version of spellcheck, and that’s exactly what makes it hard to govern: it happens in a browser tab, often on a personal account, often because no approved alternative was offered.

What Actually Happens to the Text You Paste In

Search engines index and return existing public content. Generative AI tools work differently: what a person types becomes an input the system may retain, use to improve the model, or route through human review, depending on the product’s data policy. Free and consumer-facing tiers are generally the most likely to include broad data usage rights, since input data often subsidizes free access.

This isn’t only a theoretical concern. LayerX Security’s Enterprise AI and SaaS Data Security Report 2025 found that a large share of employees using generative AI tools had copied and pasted data into their prompts, most of it from personal, unmanaged accounts outside any employer’s visibility or control. Separate 2026 industry data has tracked this trend rising sharply: DataStealth’s 2026 Enterprise Security Guide found that roughly a third of employee ChatGPT prompts now contain sensitive company data, up from around one in ten just a few years earlier. Pharma has no structural exemption from this pattern. If anything, the categories of content researchers, regulatory staff, and medical writers handle daily, unpublished trial results, formulation detail, pre-filing submission language, are exactly the kind of material this data shows employees pasting into tools with no audit trail and no contractual protection.

Why Pharma Data Carries a Different Kind of Weight

Pharma’s confidentiality obligations attach to specific categories that don’t always look sensitive on their face. Preclinical and CMC data often supports patent claims, and exposing it outside a controlled review chain can complicate patentability later. IND-enabling studies and clinical trial results are, by design, not yet public. Pharmacovigilance and adverse event reports frequently carry patient-adjacent detail that can trigger the same obligations as a direct patient data disclosure. And biomarker or genomic data sits under privacy frameworks that treat genetic information as a special, heightened category.

Geography adds another layer: HIPAA governs protected health information in the US, while the EU’s GDPR and the newer AI Act increasingly work together to regulate health-related AI use, with active enforcement already visible in fines issued against health-data processors in France.6

Why “Just Ban It” Rarely Works

The instinctive response is prohibition: block the domains, issue a policy memo. Samsung’s semiconductor division tried exactly this in 2023, after three employees pasted proprietary code and internal data into ChatGPT within a month. The ban didn’t remove the underlying need that drove the behavior, and the company ultimately built an approved internal alternative instead. Trade coverage suggests a similar pattern in pharma labs, where scientists turn to public tools when sanctioned platforms can’t do what they need. Restriction without a viable, fast alternative tends to push usage underground rather than end it.

Common Mistakes

Assuming popularity equals safety, when a tool being widely used elsewhere says nothing about whether its data terms suit pharma’s obligations. Assuming deletion equals erasure, when removing a chat from your own history doesn’t guarantee removal from a provider’s backend. And treating “non-clinical” text as low risk, when formulation notes and pre-filing language carry real exposure even without a single data point about a patient.

Best Practices

Classify data before deciding where it’s allowed to go. Provide an approved AI alternative fast enough to actually compete with the public tools people already default to. Extend governance to everyday writing and editing tools, not just formal data systems. And build training around real scenarios rather than abstract policy language, since most unauthorized use comes from convenience, not disregard for the rules.

Key Takeawcays

• Shadow AI is already documented across healthcare and life sciences, not a fringe behavior.
• Public AI tools process input in ways that differ meaningfully from a search engine query.
• Pharma data carries regulatory, patent, and privacy weight across categories like preclinical data, CMC detail, and pharmacovigilance reports.
• Restriction without a viable alternative tends to fail.
• Not all AI tools carry equal risk the specific data terms are what matter.